These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11709321)

  • 1. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
    Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
    Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
    Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
    Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
    Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
    Reid DW; Carroll V; O'May C; Champion A; Kirov SM
    Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.
    Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE
    J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum.
    Schiller NL; Millard RL
    Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
    Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
    Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum.
    Palmer KL; Aye LM; Whiteley M
    J Bacteriol; 2007 Nov; 189(22):8079-87. PubMed ID: 17873029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
    Cirioni O; Giacometti A; Ghiselli R; Orlando F; Kamysz W; D'Amato G; Mocchegiani F; Lukasiak J; Silvestri C; Saba V; Scalise G
    J Infect Dis; 2004 Jul; 190(2):356-64. PubMed ID: 15216473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability and activity in sputum of G10KHc, a potent anti-Pseudomonas antimicrobial peptide.
    Eckert R; Mchardy I; Yarbrough DK; He J; Qi F; Anderson MH; Shi W
    Chem Biol Drug Des; 2007 Nov; 70(5):456-60. PubMed ID: 17927719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR; Pressler T; Hoiby N; Johansen HK
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa.
    Barth AL; Pitt TL
    J Med Microbiol; 1996 Aug; 45(2):110-9. PubMed ID: 8683546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
    Kronborg G
    APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients.
    Ryall B; Davies JC; Wilson R; Shoemark A; Williams HD
    Eur Respir J; 2008 Sep; 32(3):740-7. PubMed ID: 18480102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.